In the BioHarmony Drug Report Database

"Preview" Icon

Eltrombopag

Promacta, Revolade (eltrombopag) is a small molecule pharmaceutical. Eltrombopag was first approved as Promacta on 2008-11-20. It is used to treat aplastic anemia and thrombocytopenic purpura idiopathic in the USA. It has been approved in Europe to treat thrombocytopenic purpura idiopathic. The pharmaceutical is active against thrombopoietin receptor. Promacta’s patents are valid until 2027-08-01 (FDA).

 

Trade Name

 

Revolade
 

Common Name

 

eltrombopag
 

ChEMBL ID

 

CHEMBL461101
 

Indication

 

aplastic anemia, thrombocytopenic purpura idiopathic
 

Drug Class

 

Thrombopoetin agonists

Image (chem structure or protein)

Eltrombopag structure rendering